Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

BACKGROUND: Heterologous vaccine regimens have been widely discussed as a way to mitigate intermittent supply shortages and to improve immunogenicity and safety of COVID-19 vaccines. We aimed to assess the reactogenicity and immunogenicity of heterologous immunisations with ChAdOx1 nCov-19 (AstraZen...

Descripción completa

Detalles Bibliográficos
Autores principales: Hillus, David, Schwarz, Tatjana, Tober-Lau, Pinkus, Vanshylla, Kanika, Hastor, Hana, Thibeault, Charlotte, Jentzsch, Stefanie, Helbig, Elisa T, Lippert, Lena J, Tscheak, Patricia, Schmidt, Marie Luisa, Riege, Johanna, Solarek, André, von Kalle, Christof, Dang-Heine, Chantip, Gruell, Henning, Kopankiewicz, Piotr, Suttorp, Norbert, Drosten, Christian, Bias, Harald, Seybold, Joachim, Klein, Florian, Kurth, Florian, Corman, Victor Max, Sander, Leif Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360702/
https://www.ncbi.nlm.nih.gov/pubmed/34391547
http://dx.doi.org/10.1016/S2213-2600(21)00357-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360702/
https://www.ncbi.nlm.nih.gov/pubmed/34391547
http://dx.doi.org/10.1016/S2213-2600(21)00357-X

Ejemplares similares